Lexeo Therapeutics, Inc. (LXEO)
(Delayed Data from NSDQ)
$12.64 USD
-0.37 (-2.84%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $12.62 -0.02 (-0.16%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
LXEO 12.64 -0.37(-2.84%)
Will LXEO be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for LXEO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LXEO
Lexeo (LXEO) Down Despite Upbeat Rare Disease Gene Therapy Data
What Makes Lexeo Therapeutics, Inc. (LXEO) a New Buy Stock
LXEO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Think Lexeo Therapeutics, Inc. (LXEO) Could Surge 57.82%: Read This Before Placing a Bet
Other News for LXEO
Lexeo Therapeutics Announces Positive Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy
Lexeo Therapeutics Announces Investor Webcast to Report Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy on Monday, July 15, 2024
Lexeo Therapeutics Appoints Tim Van Hauwermeiren to its Board of Directors
Lexeo Therapeutics initiated with bullish view at Baird, here's why
Analysts Conflicted on These Healthcare Names: Equillium (EQ), Lexeo Therapeutics, Inc. (LXEO) and Teladoc (TDOC)